

2. (Twice Amended) The method according to claim 1, wherein the drug-resistant hypercalcemia is resistant to a therapeutic agent for hypercalcemia other than said at least one substance that inhibits the binding between PTHrP and a receptor thereof.

3. (Twice Amended) The method according to claim 2, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.

4. (Amended) The method according to claim 2, wherein the therapeutic agent for hypercalcemia is a bone resorption-inhibiting agent.

5. (Twice Amended) The method according to claim 4, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.

6. (Twice Amended) The method according to any one of claims 1 or 2, wherein said at least one substance is an antagonist of the PTHrP receptor.

7. (Twice Amended) The method according to any one of claims 1 or 2, wherein said at least one substance is an anti-PTHrP antibody.

8. (Twice Amended) The method according to any one of claims 1 or 2, wherein said at least one substance is a fragment of an anti-PTHrP antibody or a modified form of the fragment.

9. (Amended) The method according to claim 7, wherein the antibody is monoclonal.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

10. (Twice Amended) The method according to claim 7, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

11. (Amended) The method according to claim 7, wherein the antibody is in a humanized form.

12. (Amended) The method according to claim 11, wherein the humanized antibody is humanized #23-57-137-1 antibody.

13. (Twice Amended) The method according to any one of claims 1 or 2, wherein the drug-resistant hypercalcemia is caused by cancer.

14. (Amended) The method according to claim 5, wherein said at least one substance is chosen from at least one of

- a) an antagonist of the PTHrP receptor;
- b) an anti-PTHrP antibody; and
- c) a fragment of an anti-PTHrP antibody or a modified form of the fragment.

15. (Amended) The method of claim 14, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

16. (Amended) The method according to claim 5, wherein the drug-resistant hypercalcemia is caused by cancer.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com